Blog by Trish Vickery On April 11, the Dana Farber IBC team held their annual patient forum; the virtual format allowed patients near and far to join. The day included informative medical presentations, followed by an expert roundtable, with a new feature –...
The FDA has approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy. Angela Alexander, PhD, Sr Clinical Studies Coordinator –...
by Terry Lynn Arnold Too many women newly diagnosed with stage IV inflammatory breast cancer (IBC) are being told that the type of cancer no longer matters. That statement should raise serious questions. Because it’s not true. IBC Is Different—From the Very Beginning...
Article by Dr. Angela Alexander On Apr 30th, the FDA approved a new first-in-class drug for the treatment of ER+ metastatic breast cancer (MBC). The new drug Vepdegestrant was approved only for patients with tumors that harbor ESR1 mutations, based on results from...
What we don’t know — and why it matters by Terry Arnold On a flight to Cleveland, the woman beside me leaned back in her seat and said in a mocking voice, “She waited too long.” It took every ounce of self-control I had. After about an hour of silence, we had started...
Co authors: Terry Arnold and Stephanie Pilkinton Every December, the global breast cancer community gathers in San Antonio, Texas, for the San Antonio Breast Cancer Symposium (SABCS) — the largest breast cancer research meeting in the world. For those of us focused on...
